The National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (BRC) is the largest BRC outside the South East of England and the beating heart of translational research across Greater Manchester, Lancashire and South Cumbria, transforming scientific breakthroughs into diagnostic tests and life-saving treatments for patients.
Awarded more than £60 million (2022-27) – the largest single research award given by the NIHR to the city region – Manchester BRC brings together world-leading researchers based at The University of Manchester and six of the country’s foremost NHS Trusts, with a vision to drive health improvements and lasting change for all through creative, inclusive and proactive research that identifies and bridges gaps between new discoveries and individualised care.
Manchester BRC is driving forward pioneering research in the areas of cancer (prevention and early detection, advanced radiotherapy, precision medicine, living with and beyond cancer), inflammation (rheumatic and musculoskeletal disease, respiratory medicine, dermatology, integrative cardiovascular medicine), high-burden under-researched conditions (hearing health, mental health, rare conditions) and advanced diagnostics and therapeutics (next generation phenotyping and diagnostics, next generation therapeutics).
Nearly three quarters of new non-cancer pain opioid prescriptions were for patients with musculoskeletal conditions, despite limited evidence of the drug’s efficacy, according to the largest UK study of its kind.
A Manchester BRC-funded study has shown that a simple system, called the Manchester Score, can identify more breast cancer patients who are eligible for testing for inherited faulty genes that can cause breast cancer.
There are plently of opportunities for people to help shape our research plans.
Research is vital to help us understand more about a particular disease or condition and how to treat them.